{"name":"Corestemchemon, Inc.","slug":"corestemchemon-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Lenzumestrocel","genericName":"Lenzumestrocel","slug":"lenzumestrocel","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Lenzumestrocel","genericName":"Lenzumestrocel","slug":"lenzumestrocel","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE5fa3BENkd2N2hMdHdNTG9seUp5Z2h3Yl9Dak1QWGREa2ZKMExsNVlLVHBMaWpqWGpLYVF2bThqWDFwbW9NNHVrcVBUQlhlRzlFZVk3bWNqVXU3N2ZFZGhrVnVLSmFlQTJ1LU1MZFZmdllBSm8?oc=5","date":"2026-02-27","type":"regulatory","source":"마켓인","summary":"Shares of Kwangdong Soar as FDA Approves Presbyopia Eye Drop...U2Bio·CorestemChemon ↑[K-Bio Pul... - 마켓인","headline":"Shares of Kwangdong Soar as FDA Approves Presbyopia Eye Drop...U2Bio·CorestemChemon ↑[K-Bio Pul... - 마켓인","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOR0JKTmVZeEkxRlpGbTlhTFgycGFEQk5nQmVWYkNjRjY1X29mQzluNVBtMEo2MkhxUUxPbWFzN0dvOW9hRGJoV0J0ZUUtci1Hc3R2LXY0UzZENzdzeWM2a3l0Q1p0bk5hT3E4SFBmZGVCdFVub0ZKOGlLUHQtazZSeEQ5QThLTlRyMjl5bXNpSGN4aEcxVkdrVXI4MVFYS2RhNUFDNnlDRHd6NjduT2Nmc3gyR3R5ZDVfei1KUmdlX0F6OFZt?oc=5","date":"2025-09-22","type":"trial","source":"BioPharma APAC","summary":"CorestemChemon Phase 3 ALSummit Trial Shows Subgroup Benefit of Neuronata-R® in ALS - BioPharma APAC","headline":"CorestemChemon Phase 3 ALSummit Trial Shows Subgroup Benefit of Neuronata-R® in ALS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxOUEpCd3dFcHB6ekgxa25ESGlQdXRueGdlcXFndUhnWHV2SlQ3QzVWUTNiaWV4WVc0T2ZrQUNYYjBYRjFVZ1FRTkh1ekdrNXAxNFNHT1pvZ0NOaG4zQmEwb3F6Q250N0s3aWx6Q3NScVhsRXhoZVRkbHNRaERRS3FWVm5iNVMwVTJfcGJvM19La3ZkYnNfVVlISmc3SVV0bF9kWTFPMDhSSUxJMXVLV2x0M014ejZmZjBzTzl4OFFEaXo5ZFQ3WG55R3hJRHBOUDNlWlZTSUJKcU1xTmZIWHBUMlBqOGVEcVhUQ0h5NlZfajgwMzUtekE?oc=5","date":"2025-09-17","type":"trial","source":"PR Newswire","summary":"Neuronata-R® Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway - PR Newswire","headline":"Neuronata-R® Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQYUNHemFIYWR5YXBnLXVDREV2UmUwZGd3dDNqbFFnNkkybTZmbjVDY2JDNGpOOHpOLXowekRyd0pqSFJNWExnUFpRLURQZnB5Q2tFNzF5WTRjbkp2WnhQYzJOQTMtWDA2Q1VLNmNEelB6YXNmdUNMcFZLQVRqV0VXbDNWZGxjTGJTMlNvaDFuVldXSWo5RzljTkUxV2dCWU9fRE1pVEJ6TFlJLU9CeTY5WUZRNC0ydw?oc=5","date":"2025-07-22","type":"deal","source":"Fierce Biotech","summary":"Korean CRO CorestemChemon inks collaboration to expand into organoids and transcriptomics - Fierce Biotech","headline":"Korean CRO CorestemChemon inks collaboration to expand into organoids and transcriptomics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxObjd1MmxWTTlpVzRlNUpPTmxvbmZwNHFaRUF0VGJlUGt2V3ZoZTh4SmxyTy1WQTZqSTk1Uk9JRTRob05talBHMUZ2TGRvN0o1bWNvRzdjMk5qTTU1d1B6enp6bU00Uk5wRTVGQ2sxd2Q0MXBUaFVlbV9KMHVWeGtFdHhjWmdrcDVGVUZMcmdnQUNpSmMzaVZwbmNFLVlseWJldWtV?oc=5","date":"2025-06-10","type":"pipeline","source":"BioWorld News","summary":"Corestemchemon preps US BLA filing for stem cell ALS therapy - BioWorld News","headline":"Corestemchemon preps US BLA filing for stem cell ALS therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOVVpsSGF3Tng5M0dIaUpUQzM0RnRtQTRkT3dvazB4NzcyRGZVMXNaejVmeERSdWRnMWsza0dtRmxyeTBmV1p5ZVlyZDBzeVZEb1N4MVF1X0VQdWM3WlF4czhvOXNsdTQ2YUxGRlRzeERvbHNBUjdkOERWbllhZ1BjVEo4Y1puYkZBUnlpSF80VlI2QVZFSzlGMkczdVZHMUhnRHhzWVhjMERPVzVLSGFYaVozX3VodzJrQmF1VXcxNWNUSFdtWEcyWkVDVUNOZDM0eC1IZVluQ20tOGh3NklWc25tcEJRQnVpRDk3X19NS1ZHSjc5d09SNUtmTk9tNnM?oc=5","date":"2025-05-29","type":"regulatory","source":"PR Newswire","summary":"Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval - PR Newswire","headline":"Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE5EZV9mYzBnNExMUDV0ZVBvLV9yOWNETk5IUXN1TnVRLTRiNDlqS0hwaTM3NzR3ZG1yZlVyLTVKM3FQTjhxYnZhd1NzOGhUVV9TamdDNnNrbFA?oc=5","date":"2019-06-15","type":"pipeline","source":"Market.us","summary":"Cell Therapy Market Size, Share | CAGR of 16.7% - Market.us","headline":"Cell Therapy Market Size, Share | CAGR of 16.7%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9BVUxHZzIxc1hPN2h5YjJkdnU3NmgyNUN0Z2NZQkNjOE9ueVdGV2MtWEtYeEN3UThOcm55REIzYUY1dHZscDFVenNSTXo1TXNpeTJhZFg4VEZqUkxuTDdV?oc=5","date":"2018-12-20","type":"regulatory","source":"Market.us","summary":"Stem Cell Therapy Market Demand, Trend Analysis | CAGR 25.3% - Market.us","headline":"Stem Cell Therapy Market Demand, Trend Analysis | CAGR 25.3%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE9CWHVETEgteGNvenZjSy1GdW5QMDdWWXVTRHZrTlJGdE8yb3BlY0twcXVBVlk2aXVVM0RlelhwTkh4RURGN2dXQUpZMV9qcXZOVGxuT0NLNVNpTGM?oc=5","date":"2018-09-20","type":"pipeline","source":"TradingView","summary":"166480 Stock Price and Chart — KRX:166480 - TradingView","headline":"166480 Stock Price and Chart — KRX:166480","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}